Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· April 4, 2026

Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years?

View original at finance.yahoo.com
Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years? What a ride it has been for Apple(NASDAQ: AAPL) and its shareholders over the years…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Apple stock has returned over 97,000% since 1990, including dividends

    60% confidence

  • Apple generated more than $123 billion in free cash flow over the past four quarters

    60% confidence

  • iPhone accounts for an estimated 32% of the global smartphone market

    60% confidence

  • Apple is still a no-brainer to buy and hold

    60% confidence

  • Apple generates a 68% return on invested capital

    60% confidence

  • Electronic devices are becoming increasingly central to modern life, so the iOS ecosystem should have long-term staying power

    60% confidence

  • The iPhone is the most popular smartphone in the United States, with a 50% to 65% market share

    60% confidence

  • There are now 2.5 billion active iOS devices worldwide

    60% confidence

  • Given Apple's $3.75 trillion market cap, investors shouldn't anticipate future performance to rival the past

    60% confidence

  • Apple is reportedly developing AI glasses that would represent a brand-new product category

    60% confidence

  • Apple evolved from an underdog in the computer market to arguably the world's most prominent consumer-facing business today

    60% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com
Apple's 50th Anniversary Was April 1. Is the Tech Giant's Stock Worth Buying and Holding for Another 50 Years? — Source | Via News | ViaNews Market